Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients

Sucampo Pharmaceuticals, Inc. (Sucampo) announced that phase 3 double blind trial of lubiprostone (marketed as AMITIZA (R) in the U.S.) for chronic idiopathic constipation (CIC) in Japanese patients has been completed (See Sucampo release dated June 8, 2010).

R-Tech Ueno has an agreement with Sucampo Pharma Ltd. (SPL), a wholly owned subsidiary of Sucampo, under which it has the exclusive right to manufacture and supply lubiprostone (marketed as AMITIZA (R)in the U.S.) in Japan, Asia, Oceania and other regions (See R-Tech Ueno release dated February 23, 2009).

The above will have no impact on our financial results for the fiscal year ending March 2011.

SOURCE R-Tech Ueno, Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Hypothalamic neurons help maintain blood sugar during daily activities